Loading…
Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment
Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such...
Saved in:
| Published in: | Journal of controlled release 2022-05, Vol.345, p.1-19 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603 |
| container_end_page | 19 |
| container_issue | |
| container_start_page | 1 |
| container_title | Journal of controlled release |
| container_volume | 345 |
| creator | Wang, Chi-Pin James Byun, Min Ji Kim, Se-Na Park, Wooram Park, Hee Ho Kim, Tae-Hyung Lee, Jung Seung Park, Chun Gwon |
| description | Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
[Display omitted]
•A detailed overview of the recent status of micro- and nano-sized drug carrier systems for IBD treatment is presented.•Various colon-targeting approaches developed for the application to natural, synthetic, and inorganic materials are reviewed.•Outlooks and immediate challenges regarding biomaterial-based IBD therapies are discussed. |
| doi_str_mv | 10.1016/j.jconrel.2022.02.028 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2634846898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016836592200102X</els_id><sourcerecordid>2634846898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMoznh5BCVLNx2TXpJ0JTp4A0EQXYc0PdEMbTMmqTJvb8qMboUDZ_P95_IhdEbJghLKLleLlXaDh26RkzxfkKnEHppTwYusrOtqH80TJ7KCVfUMHYWwIoRURckP0ayo8pxzVs7Ry411vYrgreoCVgHHD_BqDWO0Grd-fMdaeW_BB2ycx3YwnepTwPkNbtw3dLi1AVQAHD2o2MMQT9CBScPgdNeP0dvd7evyIXt6vn9cXj9lOp0UM-BVY2rC01VaG8FaQaCmrMmNpow1RhAltKlMq6HQjGte55SC4pWiBZSMFMfoYjt37d3nCCHK3gYNXacGcGOQOStKUTJRi4RWW1R7F4IHI9fe9spvJCVy0ilXcqdTTjolmWrKne9WjE0P7V_q118CrrYApEe_kiYZtIVBQ2s96ChbZ_9Z8QMdpoqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634846898</pqid></control><display><type>article</type><title>Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment</title><source>ScienceDirect Journals</source><creator>Wang, Chi-Pin James ; Byun, Min Ji ; Kim, Se-Na ; Park, Wooram ; Park, Hee Ho ; Kim, Tae-Hyung ; Lee, Jung Seung ; Park, Chun Gwon</creator><creatorcontrib>Wang, Chi-Pin James ; Byun, Min Ji ; Kim, Se-Na ; Park, Wooram ; Park, Hee Ho ; Kim, Tae-Hyung ; Lee, Jung Seung ; Park, Chun Gwon</creatorcontrib><description>Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
[Display omitted]
•A detailed overview of the recent status of micro- and nano-sized drug carrier systems for IBD treatment is presented.•Various colon-targeting approaches developed for the application to natural, synthetic, and inorganic materials are reviewed.•Outlooks and immediate challenges regarding biomaterial-based IBD therapies are discussed.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2022.02.028</identifier><identifier>PMID: 35227764</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Biocompatible Materials - therapeutic use ; Biomaterials ; Drug Carriers - therapeutic use ; Drug Delivery Systems ; Drug-delivery system ; Humans ; Hydrogel ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - drug therapy ; Microparticle ; Nanoparticle ; Polymers - therapeutic use</subject><ispartof>Journal of controlled release, 2022-05, Vol.345, p.1-19</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603</citedby><cites>FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27936,27937</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35227764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Chi-Pin James</creatorcontrib><creatorcontrib>Byun, Min Ji</creatorcontrib><creatorcontrib>Kim, Se-Na</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Park, Hee Ho</creatorcontrib><creatorcontrib>Kim, Tae-Hyung</creatorcontrib><creatorcontrib>Lee, Jung Seung</creatorcontrib><creatorcontrib>Park, Chun Gwon</creatorcontrib><title>Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
[Display omitted]
•A detailed overview of the recent status of micro- and nano-sized drug carrier systems for IBD treatment is presented.•Various colon-targeting approaches developed for the application to natural, synthetic, and inorganic materials are reviewed.•Outlooks and immediate challenges regarding biomaterial-based IBD therapies are discussed.</description><subject>Biocompatible Materials - therapeutic use</subject><subject>Biomaterials</subject><subject>Drug Carriers - therapeutic use</subject><subject>Drug Delivery Systems</subject><subject>Drug-delivery system</subject><subject>Humans</subject><subject>Hydrogel</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Microparticle</subject><subject>Nanoparticle</subject><subject>Polymers - therapeutic use</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKxDAUhoMoznh5BCVLNx2TXpJ0JTp4A0EQXYc0PdEMbTMmqTJvb8qMboUDZ_P95_IhdEbJghLKLleLlXaDh26RkzxfkKnEHppTwYusrOtqH80TJ7KCVfUMHYWwIoRURckP0ayo8pxzVs7Ry411vYrgreoCVgHHD_BqDWO0Grd-fMdaeW_BB2ycx3YwnepTwPkNbtw3dLi1AVQAHD2o2MMQT9CBScPgdNeP0dvd7evyIXt6vn9cXj9lOp0UM-BVY2rC01VaG8FaQaCmrMmNpow1RhAltKlMq6HQjGte55SC4pWiBZSMFMfoYjt37d3nCCHK3gYNXacGcGOQOStKUTJRi4RWW1R7F4IHI9fe9spvJCVy0ilXcqdTTjolmWrKne9WjE0P7V_q118CrrYApEe_kiYZtIVBQ2s96ChbZ_9Z8QMdpoqw</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Wang, Chi-Pin James</creator><creator>Byun, Min Ji</creator><creator>Kim, Se-Na</creator><creator>Park, Wooram</creator><creator>Park, Hee Ho</creator><creator>Kim, Tae-Hyung</creator><creator>Lee, Jung Seung</creator><creator>Park, Chun Gwon</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202205</creationdate><title>Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment</title><author>Wang, Chi-Pin James ; Byun, Min Ji ; Kim, Se-Na ; Park, Wooram ; Park, Hee Ho ; Kim, Tae-Hyung ; Lee, Jung Seung ; Park, Chun Gwon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biocompatible Materials - therapeutic use</topic><topic>Biomaterials</topic><topic>Drug Carriers - therapeutic use</topic><topic>Drug Delivery Systems</topic><topic>Drug-delivery system</topic><topic>Humans</topic><topic>Hydrogel</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Microparticle</topic><topic>Nanoparticle</topic><topic>Polymers - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chi-Pin James</creatorcontrib><creatorcontrib>Byun, Min Ji</creatorcontrib><creatorcontrib>Kim, Se-Na</creatorcontrib><creatorcontrib>Park, Wooram</creatorcontrib><creatorcontrib>Park, Hee Ho</creatorcontrib><creatorcontrib>Kim, Tae-Hyung</creatorcontrib><creatorcontrib>Lee, Jung Seung</creatorcontrib><creatorcontrib>Park, Chun Gwon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chi-Pin James</au><au>Byun, Min Ji</au><au>Kim, Se-Na</au><au>Park, Wooram</au><au>Park, Hee Ho</au><au>Kim, Tae-Hyung</au><au>Lee, Jung Seung</au><au>Park, Chun Gwon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2022-05</date><risdate>2022</risdate><volume>345</volume><spage>1</spage><epage>19</epage><pages>1-19</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Inflammatory bowel diseases (IBDs) are idiopathic gastrointestinal inflammatory disorders featuring chronic intestinal inflammation. Although IBDs are increasingly becoming globally prevalent, the exact etiology of IBD remains obscure. Recently, the ability of various drugs for mucosal healing such as corticosteroids, antibiotics, and immunosuppressants has been proven. However, the delivery of free drugs is insufficient and inadequate since some patients have experienced reduced efficacy due to repeated administration and others have suffered side effects. In this regard, novel platforms based on biomaterials are required to deliver pharmaceutical agents to the damaged site with increased efficacy and reduced side effects. In this review, we summarize the most recent status of numerous biomaterials in treating IBD. This review addresses various nanoparticles, microparticles, and hydrogels recently prepared from natural polymers, lipids, synthetic polymers, and inorganic materials. These diverse biomaterials can be used as effective drug-delivery systems to promote colon-specific delivery and for the stable release of drugs in IBD treatments.
[Display omitted]
•A detailed overview of the recent status of micro- and nano-sized drug carrier systems for IBD treatment is presented.•Various colon-targeting approaches developed for the application to natural, synthetic, and inorganic materials are reviewed.•Outlooks and immediate challenges regarding biomaterial-based IBD therapies are discussed.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35227764</pmid><doi>10.1016/j.jconrel.2022.02.028</doi><tpages>19</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2022-05, Vol.345, p.1-19 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2634846898 |
| source | ScienceDirect Journals |
| subjects | Biocompatible Materials - therapeutic use Biomaterials Drug Carriers - therapeutic use Drug Delivery Systems Drug-delivery system Humans Hydrogel Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Microparticle Nanoparticle Polymers - therapeutic use |
| title | Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-18T11%3A25%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomaterials%20as%20therapeutic%20drug%20carriers%20for%20inflammatory%20bowel%20disease%20treatment&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Wang,%20Chi-Pin%20James&rft.date=2022-05&rft.volume=345&rft.spage=1&rft.epage=19&rft.pages=1-19&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2022.02.028&rft_dat=%3Cproquest_cross%3E2634846898%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c365t-e75bf907000ccf86d80e916b2fc166bf80a8cf5fdce3c67c79211ea75a13e4603%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2634846898&rft_id=info:pmid/35227764&rfr_iscdi=true |